



Date: 30th January 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
Scrip Code: 539872	Symbol: BAJAJHCARE

Dear Sir/Madam,

Subject: Revised Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015

We wish to inform you that Bajaj Healthcare Limited, has received an approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule.

The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product's availability in the domestic market.

The press release in this regard, being issued by the Company is hereby submitted for your information.

Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 & the Company's code of Internal Procedures and Conduct for Regulating, monitoring & reporting of trading in securities, the Trading window for dealing in securities of the Bajaj Healthcare Limited shall continue to remain closed for all the Directors and Designated Employees in terms of our earlier disclosure dated 27th December 2024.

Kindly acknowledge and take the same on record.

Thanking You,

**For and Behalf of Board of Director of
Bajaj Healthcare Limited**

**Apurva Bandivadekar
Company Secretary & Compliance Officer**



Investor Release

Bajaj Healthcare Secures DCGI Approval for Manufacturing of Pimavanserin in India

Mumbai, 30th Jan 2025: Bajaj Healthcare Limited is proud to announce that it has received approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule. Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Pimavanserin, marketed globally as NUPLAZID[®], has become a preferred treatment in the US antipsychotic segment. In a recent update, Acadia Pharmaceuticals announced that NUPLAZID[®], along with its other brand DAYBUE[™], is projected to generate more than \$1 billion in net sales in 2025.

The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product's availability in the domestic market.

Speaking at the occasion Mr. Anil Jain, Managing Director, Bajaj Healthcare Limited, said "The approval marks a major milestone for Bajaj Healthcare. The growing success of NUPLAZID[®] in the US underscores the global demand for this innovative therapy, and we are confident that its introduction in India will be a transformative advancement in the antipsychotic segment. This move further solidifies our presence in the central nervous system (CNS) segment and highlights our dedication to advancing healthcare solutions in India.

Bajaj Healthcare, with its strong manufacturing expertise, will ensure both the API and final product meet the international quality standards. Leveraging our strong domestic presence and expertise, we aim to maximize this product's success and deliver meaningful value to the Indian market."

About Bajaj Healthcare Ltd:

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.



Contact Details

Bajaj Healthcare Ltd	Investor Relations: Orient Capital
	
CIN: L99999MH1993PLC072892	Mr. Irfan Raeen +91 9773778669/ Irfan.raeen@linkintime.co.in
Name: Mr. Anil Jain, MD	
Email: : investors@bajajhealth.com	Ms. Prachi Ambre +91 8355985370/ Prachi.ambre@linkintime.co.in

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.